ATLANTA, GA., December 09, 2012 Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma .
http://www.drugs.com/clinical_trials/once-week-oral-proteasome-inhibitor-mln9708-based-therapy-showed-response-rates-front-line-multiple-14821.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
http://www.drugs.com/clinical_trials/once-week-oral-proteasome-inhibitor-mln9708-based-therapy-showed-response-rates-front-line-multiple-14821.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
No comments:
Post a Comment